Update on the management of IgA nephropathy

Li, 2004, Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies, Kidney Int, 66, 920, 10.1111/j.1523-1755.2004.00837.x Li, 2002, Prognostic indicators of IgA nephropathy in the Chinese – clinical and pathological perspectives, Nephrol Dial Transplant, 17, 64, 10.1093/ndt/17.1.64 Hsu, 2000, Evidence for genetic factors in the development and progression of IgA nephropathy, Kidney Int, 57, 1818, 10.1046/j.1523-1755.2000.00032.x Donadio, 2002, IgA nephropathy, N Engl J Med, 347, 738, 10.1056/NEJMra020109 Eitner, 2010, Glomerular disease: ACEIs with or without corticosteroids in IgA Nephropathy?, Nat Rev Nephrol, 6, 252, 10.1038/nrneph.2010.31 Donadio, 2002, Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy, Nephrol Dial Transplant, 17, 1197, 10.1093/ndt/17.7.1197 Geddes, 2003, A tricontinental view of IgA nephropathy, Nephrol Dial Transplant, 18, 1541, 10.1093/ndt/gfg207 Alamartine, 1991, Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses, Am J Kidney Dis, 18, 12, 10.1016/S0272-6386(12)80284-8 Szeto, 2001, The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria, Am J Med, 110, 434, 10.1016/S0002-9343(01)00659-3 Berthoux, 2011, Predicting the risk for dialysis or death in IgA nephropathy, J Am Soc Nephrol, 22, 752, 10.1681/ASN.2010040355 Fogazzi, 1995, Reversible acute renal failure from gross haematuria due to glomerulonephritis: not only in IgA nephropathy and not associated with intratubular obstruction, Nephrol Dial Transplant, 10, 624 D'Amico, 1992, Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy and membranoproliferative glomerulonephritis: survey of the recent literature, Am J Kidney Dis, 20, 315, 10.1016/S0272-6386(12)70293-7 Cattran, 2009, Oxford classification of IgA nephropathy, rationale, clinicopathological correlations, and classification, Kidney Int, 76, 534, 10.1038/ki.2009.243 Cattran, 2008, The impact of sex in primary glomerulonephritis, Nephrol Dial Transplant, 23, 2247, 10.1093/ndt/gfm919 Bonnet, 2001, Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis, Am J Kidney Dis, 37, 720, 10.1016/S0272-6386(01)80120-7 Torres, 2008, The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy, Kidney Int, 73, 327, 10.1038/sj.ki.5002621 Asao, 2012, 13 relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy, Clin J Am Soc Nephrol, 7, 1385, 10.2215/CJN.08110811 Peters, 2009, Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy, Neth J Med, 67, 54 Zwirner, 1997, Activated complement C3: a potentially novel predictor of progressive IgA nephropathy, Kidney Int, 51, 1257, 10.1038/ki.1997.171 Lundberg, 2012, FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy, Clin J Am Soc Nephrol, 7, 727, 10.2215/CJN.10331011 Shi, 2012, Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial, Kidney Blood Press Res, 35, 153, 10.1159/000331453 Vuong, 2012, Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy, Kidney Int, 78, 1281, 10.1038/ki.2010.314 2012, KDIGO clinical practice guidelines for glomerulonephritis – Chapter 10: Immunoglobulin A Nephropathy, Kidney Int Suppl, 2, S209, 10.1038/kisup.2012.23 Remuzzi, 1991, Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy, Kidney Int, 39, 1267, 10.1038/ki.1991.160 Kanno, 2000, Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow up, Clin Nephrol, 54, 360 Praga, 2003, Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial, J Am Soc Nephrol, 14, 1578, 10.1097/01.ASN.0000068460.37369.DC Li, 2006, Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study, Am J Kidney Dis, 47, 751, 10.1053/j.ajkd.2006.01.017 Reid, 2011, Non immunosuppressive treatment for IgA nephropathy, Cochrane Database Syst Rev, CD003962 Russo, 1999, Addictive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy, Am J Kidney Dis, 33, 851, 10.1016/S0272-6386(99)70416-6 Russo, 2001, Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy, Am J Kidney Dis, 38, 18, 10.1053/ajkd.2001.25176 Yusuf, 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med, 358, 1547, 10.1056/NEJMoa0801317 Mann, 2008, Renal outcomes with Telmisartan, ramipril or both in people at high vascular risk (the ONTARGET study): a multicenter, randomised, double blind, controlled trial, Lancet, 372, 547, 10.1016/S0140-6736(08)61236-2 Donadio, 1999, The long-term outcome of patients with IgA nephropathy treated with fish-oil in a controlled trial, J Am Soc Nephrol, 10, 1772, 10.1681/ASN.V1081772 Taji, 2006, Meta-analysis of antiplatelet therapy for IgA nephropathy, Clin Exp Nephrol, 10, 268, 10.1007/s10157-006-0433-8 Xie, 2004, Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy, Kidney Int, 65, 1135, 10.1111/j.1523-1755.2004.00486.x Rasche, 1999, Tonsillectomy does not prevent a progressive course in IgA nephropathy, Clin Nephrol, 51, 147 Smerud, 2011, New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria, Nephrol Dial Transplant, 26, 3237, 10.1093/ndt/gfr052 Rostoker, 1989, Serum IgG subclasses and IgM imbalances in adult IgA mesangial glomerulonephritis and idiopathic Henoch-Schoelein purpura, Clin Exp Immunol, 75, 30 Rostoker, 1994, High dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Scholein purpura, Ann Intern Med, 120, 476, 10.7326/0003-4819-120-6-199403150-00005 Coppo, 1990, Effects of a gluten-free diet in primary IgA nephropathy, Clin Nephrol, 33, 72 Strippoli, 2003, An “evidence-based” survey of therapeutic options for IgA nephropathy: assessment and criticism, Am J Kidney Dis, 41, 1129, 10.1016/S0272-6386(03)00344-5 Lv, 2012, Corticosteroid therapy in IgA nephropathy, J Am Soc Nephrol, 23, 1108, 10.1681/ASN.2011111112 Hogg, 2006, Clinical trial to evaluate omego-3 fatty acids and alternate day prednisone in patients with IgAN: report from the Southwest Paediatric Nephrology Study Group, Clin J Am Soc Nephrol, 1, 467, 10.2215/CJN.01020905 Pozzi, 1999, Corticosteroids in IgA nephropathy: a randomized controlled trial, Lancet, 353, 883, 10.1016/S0140-6736(98)03563-6 Pozzi, 2004, Corticosteroid effectiveness IgA nephropathy: long term results of a randomized, controlled trial, J Am Soc Nephrol, 15, 157, 10.1097/01.ASN.0000103869.08096.4F Manno, 2009, Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy, Nephrol Dial Transplant, 24, 3694, 10.1093/ndt/gfp356 Katafuchi, 2003, Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisone therapy, Am J Kidney Dis, 41, 972, 10.1016/S0272-6386(03)00194-X Ballardie, 2002, Controlled prospestive trial of prednisolone and cytotoxics in progressive IgA nephropathy, J Am Soc Nephrol, 13, 142, 10.1681/ASN.V131142 Pozzi, 2010, Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy, J Am Soc Nephrol, 21, 1783, 10.1681/ASN.2010010117 Barratt, 2006, Treatment of IgA nephropathy, Kidney Int, 69, 1934, 10.1038/sj.ki.5000419 Axelopoulos, 2004, Treatment of primary IgA nephropathy, Kidney Int, 65, 341, 10.1111/j.1523-1755.2004.00437.x Yoshikawa, 1999, A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA nephropathy Treatment Study Group, J Am Soc Nephrol, 10, 101, 10.1681/ASN.V101101 Welch, 1998, Rapidly progressive IgA nephropathy, Am J Dis Child, 142, 15 Lai, 1987, Plasma exchange in patients with rapidly progressive idiopathic IgA nephropathy: a report of two cases and review of literature, Am J Kidney Dis, 10, 66, 10.1016/S0272-6386(87)80014-8 Fisch, 2005, Mycophenolate mofetil (MMF) Vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial, Nephrol Dial Transplant, 20, 2139, 10.1093/ndt/gfh974 Tang, 2005, Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy, Kidney Int, 68, 802, 10.1111/j.1523-1755.2005.00460.x Tang, 2010, Long-term study of mycophenolate mofetil treatment in IgA nephropathy, Kidney Int, 77, 543, 10.1038/ki.2009.499 Lai, 1987, Cyclosporin treatment of IgA nephropathy: a short term controlled trial, Br Med J (Clin Res Ed), 295, 1165, 10.1136/bmj.295.6607.1165 Cattran, 1991, Current status of cyclosporin A in the treatment of membranous. IgA and membranoproliferative glomerulonephritis, Clin Nephrol, 35, S43 Shin, 2005, Cyclosporin A therapy for severe Henoch-Scholein nephritis with nephrotic syndrome, Pediatr Nephrol, 20, 1093, 10.1007/s00467-005-1864-2 Kim, 2009, Clinicopathologic characteristics of IgAN with steroid responsive nephrotic syndrome, J Korean Med Sci, 24, S44, 10.3346/jkms.2009.24.S1.S44 Lai, 1986, Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial, Clin Nephrol, 26, 174 Mustonen, 1983, The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy, Clin Nephrol, 20, 172 Cheng, 1989, Mesangial IgA nephropathy with steroid responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid induced remission, Am J Kidney Dis, 14, 361, 10.1016/S0272-6386(89)80168-4 Abe, 1986, Participation of extra capillary lesions (ECL) in progression of IgA nephropathy, Clin Nephrol, 25, 37 Pankhurst, 2009, vasculitic IgAN: prognosis and outcome, Nephron Clin Pract, 112, c16, 10.1159/000210570 Pankhurst, 2009, Vasculictic IgA nephropathy: prognosis and outcome, Nephron Clin Pract, 112, c16, 10.1159/000210570 Tumilin, 2003, Crescentic, proliferative IgA nephropathy: clinical and histological response to methyl prednisolone and intravenous cyclophosphamide, Nephrol Dial Transplant, 18, 1321, 10.1093/ndt/gfg081 Tang, 2002, Idiopathic IgA nephropathy with diffuse crescent formation, Am J Nephrol, 22, 480, 10.1159/000065281 Gutierrez, 2007, Factors that determine an incomplete recovery of renal function in macro hematuria- induced acute renal failure of IgA nephropathy, Clin J Am Soc Nephrol, 2, 51, 10.2215/CJN.02670706 Praga, 1985, Acute worsening of renal function during episodes of macroscopic hematuria in IgA nephropathy, Kidney Int, 28, 69, 10.1038/ki.1985.120